期刊
BLOOD
卷 120, 期 16, 页码 3318-3325出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2012-05-432575
关键词
-
类别
资金
- National Heart, Lung, and Blood Institute [HL096497-01]
- Amgen
- Cangene
- GlaxoSmithKline
- Genzyme
- IgG of America
- Immunomedics
- Ligand
- Eisai Inc
- Shionogi
- Sysmex
B lymphocytes producing antiplatelet autoantibodies play a major role in autoimmune thrombocytopenia (ITP). However, certain B cells, including the human CD19(+)CD24(hi)CD38(hi) subpopulation, possess regulatory functions mediated partly by IL-10. In a cohort of chronic ITP patients with low platelet counts who consisted of patients off treatment, we found a lower frequency of CD19(+)CD24(hi)CD38(hi) in the peripheral compartment of nonsplenectomized patients (P = .03). IL-10 expression after activation was decreased in all ITP circulating CD19(+) subpopulations (P < .03), and inhibition of monocyte TNF-alpha expression by activated B cells was reduced in patients with platelet numbers of < 50 x 10(9) cells/L (P = .001), indicating that regulatory B cells of patients with ITP are functionally impaired in their ability to dampen monocyte activation. Interestingly, in nonsplenectomized patients whose platelet counts were elevated after treatment with thrombopoietic agents, the frequency of CD19(+)CD24(hi)CD38(hi) B cells was increased compared with those before treatment (P = .02). Altogether, these data indicate a compromised regulatory B-cell compartment as an additional defect in immune regulation in patients with chronic ITP that may be restored in responders to thrombopoietic treatment. (Blood. 2012;120(16):3318-3325)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据